Edgewise Delivers Positive Phase 2 HCM Data and Q2 Results; Pro Forma Cash Hits $2B After Servier Deal
EWTX has more than doubled off its 52-week low of $12.3.
Summary
Edgewise announced positive Phase 2 data for EDG-7500 in HCM and reported Q2 2026 results, with a pro forma cash balance of $2.01B following the $1.55B Servier upfront payment, positioning the company to advance its cardiovascular pipeline without near-term financing needs.
Key Events · Earnings and Guidance · EWTX
-
Positive Phase 2 CIRRUS-HCM Data
EDG-7500 delivered positive top-line results in a 12-week open-label trial across obstructive and nonobstructive HCM, supporting advancement to a Phase 3 trial expected to start in Q4 2026.
-
Pro Forma Cash of $2.01B
Cash and equivalents stood at $460.7M as of June 30, 2026; adding the $1.55B upfront from the Servier deal closed July 10, 2026, yields a pro forma balance of $2.01B before taxes and transaction costs.
-
Q2 2026 Financial Results
A net loss of $57.3M ($0.53/share) was recorded, with R&D spend of $47.5M and G&A of $14.4M, reflecting increased clinical activity for EDG-7500 and EDG-15400.
-
EDG-15400 Phase 2 Trial Planned
A Phase 2 trial in heart failure with preserved ejection fraction (HFpEF) is expected to begin in the second half of 2026, following completion of a Phase 1 study in healthy adults.
Analysis · EWTX · Life Sciences
Positive top-line results from the Phase 2 CIRRUS-HCM trial of EDG-7500 in both obstructive and nonobstructive HCM were disclosed, a key value driver for the newly cardiovascular-focused company. The data de-risks the program ahead of a planned Phase 3 start in Q4 2026. Q2 financials show a net loss of $57.3M, but the balance sheet is transformed by the $1.55B upfront from the Servier sale, resulting in a pro forma cash position of $2.01B — enough to fund operations through multiple clinical milestones without near-term dilution risk. The pipeline update also includes EDG-15400 advancing to a Phase 2 trial in HFpEF in H2 2026, broadening the cardiovascular portfolio.
At the time of this filing, EWTX was trading at $44.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8B. The 52-week trading range was $12.30 to $48.40. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.